The long‐term effects of faecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent Clostridium difficile infection
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Summary: Background: Faecal microbiota transplantation (FMT) is an effective treatment for recurrent Clostridium difficile infection. In short‐term the treatment has been shown to be safe, however, there are no large, long‐term follow‐up studies looking into the potential adverse effects. Aim: To analyse the long‐term effect of FMT treatment in patients with recurrent C. difficile infection and to compare the outcome to antibiotic treated patients. Methods: Altogether 84 patients of which 45 received a FMT treatment and 39 served as controls receiving antibiotics for the infection were followed on average for 3.8 years. Their recovery and medical status was evaluated using a retrospective questionnaire, determining their quality of life, gastrointestinal symptoms and new diseases potentially related to the FMT. Results: There was no difference in the incidence of severe diseases (inflammatory bowel disease, cancer, autoimmune disease, allergy, neurological diseases) between the patient groups. In addition, weight gain did not differ between treatment groups. The FMT treated patients reported that their bowel habits improved significantly faster, they had less irregular bowel function and less symptoms of upper GI‐tract when compared to the patients treated with antibiotics. Significantly more patients in FMT‐group reported that their mental health improved after the treatment. The willingness to receive FMT treatment for potential new C. difficile infection was significantly higher in both treatment groups compared to other treatment options. Conclusion: Our study highlights that FMT is a durable, safe and acceptable treatment option for patients with recurrent C. difficile infection also in long term, and it shows potential benefits over antimicrobial treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 1×
“difficile infection has been shown to be greatly impoverished due to both the condition and the antimicrobial treatments attempted for treatment.(2,28) We recently showed that the intestinal microbiota composition of a C.”
BackgroundEuropean consensus conference on faecal microbiota transplantation in clinical practice
Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313017 · Cited by 1,207
From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways
Rogers, G. B., Keating, D. J., Young, R. L., Wong, M.-L., Licinio, J., & Wesselingh, S. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.50 · Cited by 969 · cited 1×
“Vice versa, changes in behaviour can also alter gut microbiota composition.(36) The use of broad-spectrum antibiotics, particularly macrolides or tetracyclines, has been speculated to be associated with IBS development in this patient group, linking the C.”
BackgroundKassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904
Brandt, L. J., Aroniadis, O. C., Mellow, M., Kanatzar, A., Kelly, C., Park, T., Stollman, N., Rohlke, F., & Surawicz, C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.60 · Cited by 672 · cited 1×
“The long-term safety of FMT has been under a lot of discussion, and several studies have pointed out the need for longer follow-up times where adverse effects are actively sought.(17,25,31) Especially the development of extra-intestinal conditions, such as autoimmune diseases or weight gain, has been 35 * * P-value = .”
BackgroundQuraishi, M. N., Widlak, M., Bhala, N., Moore, D., Price, M., Sharma, N., & Iqbal, T. H. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14201 · Cited by 617
Neal, K. R., Hebden, J., & Spiller, R. (1997) · BMJ · doi:10.1136/bmj.314.7083.779 · Cited by 586
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook
Kelly, C. R., Kahn, S., Kashyap, P., Laine, L., Rubin, D., Atreja, A., Moore, T., & Wu, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.008 · Cited by 572 · cited 1×
“In addition, the FMT has been rising hopes as a new treatment avenue for other diseases such as irritable bowel syndrome and more systematic conditions such as metabolic syndrome.(5,6) Regardless of the high interest towards FMT treatment, there are still some concerns regarding the risk of transmission of other disea…”
BackgroundCammarota, G., Ianiro, G., & Gasbarrini, A. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000046 · Cited by 428
Mattila, E., Uusitalo–Seppälä, R., Wuorela, M., Lehtola, L., Nurmi, H., Ristikankare, M., Moilanen, V., Salminen, K., Seppälä, M., Mattila, P. S., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.11.037 · Cited by 371 · cited 1×
“The screening of the donor and the faecal transplantation process has been previously described.(1,26) Stool was donated by either the patient’s relatives, individuals in intimate physical contact with the patient such as their spouse or universal donors.”
MethodSelf-citation
Cited by
Aron-Wisnewsky, J., Warmbrunn, M. V., Nieuwdorp, M., & Clément, K. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.10.057 · Cited by 452
Hvas, C. L., Dahl Jørgensen, S. M., Jørgensen, S. P., Storgaard, M., Lemming, L., Hansen, M. M., Erikstrup, C., & Dahlerup, J. F. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.019 · Cited by 390
The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications.
Allegretti, J. R., Mullish, B. H., Kelly, C., & Fischer, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31266-8 · Cited by 358
Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology
Khoruts, A., Staley, C., & Sadowsky, M. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0350-4 · Cited by 155
Ianiro, G., Masucci, L., Quaranta, G., Simonelli, C., Lopetuso, L. R., Sanguinetti, M., Gasbarrini, A., & Cammarota, G. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14816 · Cited by 152
Metadata
- Authors
- Jalanka, J., Hillamaa, A., Satokari, R., Mattila, E., Anttila, V. ‐., & Arkkila, P.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2017-12-11
- Volume
- 47
- Issue
- 3
- Pages
- 371-379
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2772501635
- Cited by
- 63
- References
- 15
- FWCI
- 4.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The long‐term effects of faecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent Clostridium difficile infection. https://app.cochat.ai/papers/10.1111/apt.14443
- The paper
- Jalanka, J., Hillamaa, A., Satokari, R., Mattila, E., Anttila, V. ‐., & Arkkila, P. (2018). The long‐term effects of faecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent Clostridium difficile infection. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.14443
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.